Abbott beats quarterly profit, but pulls forecast on coronavirus concerns

This post was originally published on this site

Shares of the company, which makes products ranging from laboratory test kits to children’s protein drink PediaSure, rose 2% in premarket trading.

Abbott has launched three coronavirus tests in the United States, including an on-site diagnostic kit that can deliver results within minutes and heralded as a game changer by President Donald Trump.

However, sales in its diagnostics unit fell nearly 1% to $1.83 billion, as increased use of its tests for the fast-spreading virus could not offset the decline in demand for its other diagnostic tests.

Sales at the company’s nutrition products division rose 6.3% to $1.90 billion, benefiting from increased demand for children’s products in late March as U.S. states began to impose shelter-in-place restrictions to curb the spread of the virus.

The company’s net earnings fell to $564 million, or 31 cents per share, in the first quarter ended March 31, from $672 million, or 38 cents per share, a year earlier.

Excluding items, it earned 65 cents per share, above the average analyst estimate of 58 cents per share, according to Refinitiv data.

Net sales rose 2.5% to $7.73 billion, ahead of the average estimate of $7.34 billion.